Belite Bio Insider Sell‑Off: CEO, CFO & Scientist Divest 16,666 Shares as Company Balances Cash Flow and Clinical Pipeline Expectations
Belite Bio insider sell‑off signals portfolio rebalancing, not a bearish trend, as executives lock in gains while the company’s clinical pipeline faces cash‑flow pressure.
3 minutes to read